Metropolis Healthcare quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	450	386	+16.6%
EBITDA	111	89.8	+23.9%
EBITDA margin	24.7%	23.3%	+1.4 pts
Profit before tax	77.7	61.2	+26.9%
Net profit	56.9	45.2	+25.7%
EPS	₹2.73	₹8.70	−68.6%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	450	425	406	429	386	345	323	350	313	331	291	309	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	5.1	8.2	9.0	0.9	7.5	7.0	2.6	3.1	2.5	2.5	2.3	1.2
	455	433	415	430	394	352	325	353	316	334	293	310
	87.1	78.5	79.2	87.7	79.0	71.5	64.5	69.5	63.2	67.1	57.2	61.3
	107	95.5	94.2	95.4	92.3	82.2	81.4	78.4	71.7	71.5	69.5	69.8
	6.2	7.9	5.7	5.7	5.2	4.6	4.5	4.8	4.7	5.6	5.3	5.7
	32.4	38.6	31.9	32.4	30.8	28.6	27.7	26.8	25.5	26.4	25.0	22.2
	145	143	138	138	125	129	105	112	99.7	112	99.5	103
	378	363	349	359	332	316	283	292	265	283	257	262
	111	108	94.8	108	89.8	62.3	72.0	89.9	78.8	80.0	64.8	74.8
	78.8	69.4	63.0	75.8	58.9	33.7	44.3	63.1	53.3	53.6	39.9	52.6
Profit
	77.7	69.7	66.3	71.0	61.2	36.0	42.3	61.4	51.1	50.5	36.9	48.1
	0.0	0.1	−9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	77.7	69.8	57.2	71.0	61.2	36.0	42.3	61.4	51.1	50.5	36.9	48.1
	21.0	22.5	13.3	20.2	17.6	8.6	11.2	15.4	13.5	14.0	10.2	14.3
	−0.2	−3.7	1.7	−2.1	−1.6	−1.7	−0.3	−0.7	−0.5	−0.0	−0.7	−1.9
	20.8	18.8	15.1	18.1	16.0	6.8	10.9	14.7	13.0	14.0	9.6	12.5
	56.9	51.0	42.1	52.9	45.2	29.2	31.5	46.7	38.1	36.5	27.3	35.7
	56.9	51.0	42.1	52.9	45.2	29.2	31.5	46.7	38.1	36.5	27.3	35.7
	2.8	3.4	1.6	2.0	−2.2	1.0	−1.8	−0.7	1.1	5.9	−0.4	−4.1
	59.7	54.3	43.7	54.9	43.1	30.3	29.7	46.0	39.2	42.5	26.9	31.6
	56.7	50.9	41.4	52.7	45.1	29.1	31.4	46.5	37.9	36.4	27.2	35.5
	0.2	0.1	0.7	0.2	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.2
Per share
	₹2.73	₹2.46	₹7.99	₹10.17	₹8.70	₹5.69	₹6.11	₹9.08	₹7.41	₹7.11	₹5.30	₹6.92
	₹2.73	₹2.46	₹7.94	₹10.13	₹8.66	₹5.66	₹6.09	₹9.03	₹7.37	₹7.08	₹5.28	₹6.90
Other comprehensive income — detail
	2.8	3.4	1.6	2.0	−2.2	1.0	—	—	—	—	—	—
	—	0.5	—	—	—	—	—	—	−0.6	—	—	—
	−0.1	0.2	−2.3	1.8	0.4	−1.0	—	—	—	—	—	—
	—	—	—	—	—	—	0.7	1.5	−0.1	−0.6	0.7	1.1
	—	0.0	—	—	—	—	—	—	1.5	—	—	—
	−2.7	−3.0	0.6	−3.8	1.7	−0.0	—	—	—	—	—	—
	—	—	—	—	—	—	1.0	−0.8	0.0	−5.4	−0.3	3.0
	59.5	54.2	43.0	54.7	42.9	30.2	29.6	45.9	39.0	42.3	26.8	31.4
	0.2	0.1	0.7	0.2	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.2
Per share — as-filed variants
	₹2.73	₹2.46	₹7.99	₹10.17	₹8.70	₹5.69	₹6.11	₹9.08	₹7.41	₹7.11	₹5.30	₹6.92
	₹2.73	₹2.46	₹7.94	₹10.13	₹8.66	₹5.66	₹6.09	₹9.03	₹7.37	₹7.08	₹5.28	₹6.90
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	363	346	327	341	307	274	258	280	250	264	234	247
	80.7%	81.5%	80.5%	79.6%	79.5%	79.3%	80.0%	80.1%	79.8%	79.7%	80.3%	80.1%
Adjusted (ex-exceptional items) — derived
	77.7	69.7	66.3	71.0	61.2	36.0	42.3	61.4	51.1	50.5	36.9	48.1
	0.0	0.1	−9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	56.9	50.9	48.8	52.9	45.2	29.2	31.5	46.7	38.1	36.5	27.3	35.7
	₹2.73	₹2.46	₹9.26	₹10.17	₹8.70	₹5.69	₹6.11	₹9.08	₹7.41	₹7.11	₹5.30	₹6.92

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

METROPOLIS₹551.20

Metropolis Healthcare Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersLALPATHLAB VIJAYA THYROCARE MARKSANS PARKHOSPS JLHL RUBICON HCGMcap ₹11,428 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	308.5	291.1	331.0	313.4	349.8	322.8	345.3	386.1	429.2	405.9	424.7	450.2
Other Income	1.2	2.3	2.5	2.5	3.1	2.6	7.0	7.5	0.9	9.0	8.2	5.1
Total Income	309.7	293.4	333.5	315.8	352.9	325.3	352.3	393.6	430.1	414.9	432.8	455.3
Expenses
+ Cost of Materials Consumed	61.3	57.2	67.1	63.2	69.5	64.5	71.5	79.0	87.7	79.2	78.5	87.1
+ Employee Benefit Expense	69.8	69.5	71.5	71.7	78.4	81.4	82.2	92.3	95.4	94.2	95.5	107.0
+ Finance Costs	5.7	5.3	5.6	4.7	4.8	4.5	4.6	5.2	5.7	5.7	7.9	6.2
+ Depreciation & Amortisation	22.2	25.0	26.4	25.5	26.8	27.7	28.6	30.8	32.4	31.9	38.6	32.4
+ Other Expenses	102.7	99.5	112.5	99.7	112.0	104.8	129.3	125.0	137.8	137.6	142.7	144.9
Total Expenses	261.6	256.6	283.0	264.7	291.5	283.0	316.2	332.3	359.1	348.7	363.2	377.6
EBITDA	74.8	64.8	80.0	78.8	89.9	72.0	62.3	89.8	108.2	94.8	108.0	111.2
EBIT	52.6	39.9	53.6	53.3	63.1	44.3	33.7	58.9	75.8	63.0	69.4	78.8
Profit
PBT before Exceptional Items	48.1	36.9	50.5	51.1	61.4	42.3	36.0	61.2	71.0	66.3	69.7	77.7
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.1	0.1	0.0
Pretax Income	48.1	36.9	50.5	51.1	61.4	42.3	36.0	61.2	71.0	57.2	69.8	77.7
+ Current Tax	14.3	10.2	14.0	13.5	15.4	11.2	8.6	17.6	20.2	13.3	22.5	21.0
+ Deferred Tax	-1.9	-0.7	-0.0	-0.5	-0.7	-0.3	-1.7	-1.6	-2.1	1.7	-3.7	-0.2
Tax Expense	12.5	9.6	14.0	13.0	14.7	10.9	6.8	16.0	18.1	15.1	18.8	20.8
Net Income	35.7	27.3	36.5	38.1	46.7	31.5	29.2	45.2	52.9	42.1	51.0	56.9
+ Net Income — Continuing Ops	35.7	27.3	36.5	38.1	46.7	31.5	29.2	45.2	52.9	42.1	51.0	56.9
+ Other Comprehensive Income	-4.1	-0.4	5.9	1.1	-0.7	-1.8	1.0	-2.2	2.0	1.6	3.4	2.8
Total Comprehensive Income	31.6	26.9	42.5	39.2	46.0	29.7	30.3	43.1	54.9	43.7	54.3	59.7
Net Income to Common	35.5	27.2	36.4	37.9	46.5	31.4	29.1	45.1	52.7	41.4	50.9	56.7
Minority Interest	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0.2	0.7	0.1	0.2
Per Share
Basic EPS	6.92	5.30	7.11	7.41	9.08	6.11	5.69	8.70	10.17	7.99	2.46	2.73
Diluted EPS	6.90	5.28	7.08	7.37	9.03	6.09	5.66	8.66	10.13	7.94	2.46	2.73
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	1.0	-2.2	2.0	1.6	3.4	2.8
+ Items NOT to be Reclassified to P&L	—	—	—	-0.6	—	—	—	—	—	—	0.5	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-1.0	0.4	1.8	-2.3	0.2	-0.1
+ Tax on Items NOT to be Reclassified — alt tag	1.1	0.7	-0.6	-0.1	1.5	0.7	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	1.5	—	—	—	—	—	—	0.0	—
+ Tax on Items to be Reclassified	—	—	—	—	—	—	-0.0	1.7	-3.8	0.6	-3.0	-2.7
+ Tax on Items to be Reclassified — alt tag	3.0	-0.3	-5.4	0.0	-0.8	1.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	31.4	26.8	42.3	39.0	45.9	29.6	30.2	42.9	54.7	43.0	54.2	59.5
Comprehensive Income — Non-controlling Interests	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0.2	0.7	0.1	0.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	6.92	5.30	7.11	7.41	9.08	6.11	5.69	8.70	10.17	7.99	2.46	2.73
Diluted EPS — Continuing Operations	6.90	5.28	7.08	7.37	9.03	6.09	5.66	8.66	10.13	7.94	2.46	2.73
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	247.2	233.9	263.9	250.2	280.3	258.2	273.8	307.0	341.4	326.7	346.2	363.1
Gross Margin %	80.14	80.33	79.73	79.85	80.14	80.00	79.28	79.52	79.55	80.48	81.52	80.65
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	48.1	36.9	50.5	51.1	61.4	42.3	36.0	61.2	71.0	66.3	69.7	77.7
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-9.1	0.1	0.0
Net Income Adj (tax-effected)	35.7	27.3	36.5	38.1	46.7	31.5	29.2	45.2	52.9	48.8	50.9	56.9
EPS Adj	6.92	5.30	7.11	7.41	9.08	6.11	5.69	8.70	10.17	9.26	2.46	2.73
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	10.2	10.2	10.2	10.2	10.2	10.3	10.4	10.4	10.4	10.4	41.5	41.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Metropolis Healthcare Q2 FY27 results date

Metropolis Healthcare (NSE: METROPOLIS) will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, according to the board-meeting notice it filed on 28 October 2026, which also lists a dividend. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹56.7 crore, up 25.8% from ₹45.1 crore in Q1 FY26 and up 11.3% from ₹50.9 crore in Q4 FY26. Revenue from operations was ₹450 crore, up 16.6% year on year and up 6.0% from the previous quarter.

Board-meeting notice filed: 28 October 2026
Q2 FY26 results (a year earlier): 4 November 2025
Q1 FY27 results (the latest): 4 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 3 November 2026Tuesday · notice filed 28 Oct
Q1 FY27 net profit: ₹56.7 Cr+25.8% vs Q1 FY26+11.3% vs Q4 FY26
Q1 FY27 revenue: ₹450 Cr+16.6% vs Q1 FY26+6.0% vs Q4 FY26
Q1 FY27 operating margin: 17.5%+2.2 pts vs Q1 FY26+1.2 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹52.7 CrRevenue ₹429 Cr
Q1 FY27 EPS (basic): ₹2.73

Questions

When will Metropolis Healthcare announce its Q2 FY27 results?

On 3 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 28 October 2026). Last year it reported Q2 FY26 on 4 November 2025.

What were Metropolis Healthcare's Q1 FY27 results?

Consolidated net profit was ₹56.7 crore, up 25.8% from ₹45.1 crore in Q1 FY26 and up 11.3% from ₹50.9 crore in Q4 FY26. Revenue from operations was ₹450 crore, up 16.6% year on year and up 6.0% from the previous quarter.

What was Metropolis Healthcare's net profit in FY26?

Consolidated net profit was ₹190 crore in FY26 (April 2025–March 2026), up 31.1% from ₹145 crore in FY25. It was ₹128 crore in FY24 and ₹143 crore in FY23: up 33.0% over three years, 10.0% a year on average.

What will Metropolis Healthcare's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹52.7 crore and revenue from operations ₹429 crore. The latest quarter, Q1 FY27, had a net profit of ₹56.7 crore and revenue of ₹450 crore.

How has Metropolis Healthcare's profit changed over the last four quarters?

Net profit by quarter: ₹52.7 crore in Q2 FY26, ₹41.4 crore in Q3 FY26, ₹50.9 crore in Q4 FY26 and ₹56.7 crore in Q1 FY27. That is ₹202 crore over the four quarters, up 32.6% from ₹152 crore in the four quarters before. Revenue from operations: ₹429 crore, ₹406 crore, ₹425 crore and ₹450 crore.

What was Metropolis Healthcare's revenue in FY26?

Revenue from operations was ₹1,646 crore in FY26 (April 2025–March 2026), up 23.6% from ₹1,331 crore in FY25. It was ₹1,208 crore in FY24 and ₹1,148 crore in FY23: up 43.3% over three years, 12.8% a year on average.

Where do these Metropolis Healthcare figures come from?

From Metropolis Healthcare's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.